Albert D Windhorst
Overview
Explore the profile of Albert D Windhorst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
253
Citations
4546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knip J, Iqbal R, Bonjer E, Mammatas L, van Zweeden A, Perin P, et al.
Radiology
. 2025 Mar;
314(3):e241850.
PMID: 40035673
Background According to current guidelines, staging of patients with locally advanced breast cancer and local-regional recurrent breast cancer is preferably performed with PET using 2-fluorine 18-fluoro-2-deoxy-d-glucose (F-FDG). However, F-FDG PET...
2.
Beaino W, Jm Kooijman E, Werry E, Vellinga R, Van den Hoek J, Sohler G, et al.
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 39907797
Purpose: The translocator protein 18 kDa (TSPO) is a widely used marker for imaging neuroinflammation via Positron Emission Tomography (PET). However, the vast majority of reported TSPO PET tracers display...
3.
Palard-Novello X, Henrar R, Oprea-Lager D, Cysouw M, Schober P, de Geus-Oei L, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
52(4):1472-1480.
PMID: 39743615
Purpose: The aim of this study was to validate simplified methods for quantifying [Ga]Ga-FAPI-46 uptake against full pharmacokinetic modeling. Methods: Ten patients with pancreatobiliary cancer underwent a 90-min dynamic PET/CT...
4.
Wuensche T, Pereira P, Windhorst A, Bjerregaard-Andersen K, Sotty F, Kallunki P, et al.
Nucl Med Biol
. 2024 Nov;
140-141:108969.
PMID: 39591759
Background: Recently, Zr-immuno-PET imaging of therapeutic antibodies, actively transported over the blood-brain-barrier via transferrin-mediated transcytosis, was demonstrated using the chelator DFO*. In these studies, aducanumab targeting amyloid-beta was fused with...
5.
Haveman L, de Kruijff A, van Eeden S, Windhorst A, Vugts D
Chemistry
. 2024 Nov;
31(2):e202403127.
PMID: 39530382
Fluorine-18 is the predominant radionuclide used to label Positron Emission Tomography (PET) tracers. One outstanding challenge in nucleophilic aromatic radiofluorination reactions is the sensitivity of precursors and catalysts for basic...
6.
Wijngaarden J, Slebe M, Pouw J, Oprea-Lager D, Schuit R, Dickhoff C, et al.
Eur J Nucl Med Mol Imaging
. 2024 Oct;
52(2):719-729.
PMID: 39377810
Introduction: The novel positron emission tomography (PET) imaging tracer, [F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was...
7.
Steen E, Vugts D, Windhorst A
Front Nucl Med
. 2024 Oct;
2:853475.
PMID: 39354992
Designing positron emission tomography (PET) tracers for targets in the central nervous system (CNS) is challenging. Besides showing high affinity and high selectivity for their intended target, these tracers have...
8.
Veth L, Windhorst A, Vugts D
Angew Chem Int Ed Engl
. 2024 Sep;
64(4):e202416901.
PMID: 39349368
The development of new tracers for positron emission tomography (PET) is highly dependent on the available synthetic tools for their radiosynthesis. Herein, we present the radiosynthesis and application of [F]trifluoroiodomethane...
9.
Ciggaar I, de Muynck L, de Geus-Oei L, van Velden F, de Kroon C, Arias-Bouda L, et al.
Nucl Med Biol
. 2024 Sep;
138-139:108952.
PMID: 39326323
Purpose: The selection for either primary or interval cytoreductive surgery (CRS) in patients with epithelial ovarian cancer (EOC) is currently based on imaging techniques like computed tomography (CT), [F]fluorodeoxyglucose-positron emission...
10.
Wuensche T, Stergiou N, Mes I, Verlaan M, Kooijman E, Windhorst A, et al.
Mol Imaging Biol
. 2024 Aug;
26(5):823-834.
PMID: 39093482
Purpose: In the emerging field of antibody treatments for neurodegenerative diseases, reliable tools are needed to evaluate new therapeutics, diagnose and select patients, monitor disease progression, and assess therapy response....